General Information of Drug Combination (ID: DCALE5O)

Drug Combination Name
BIO-300 Arfolitixorin
Indication
Disease Entry Status REF
Anaplastic large cell lymphoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Arfolitixorin   DMIXMYK
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SR
Zero Interaction Potency (ZIP) Score: 4.95
Bliss Independence Score: 4.73
Loewe Additivity Score: 4.29
LHighest Single Agent (HSA) Score: 7.15

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCMPTLK HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCO6IUI MOLT-4 Investigative [1]
Glioma DCMHNI8 SF-268 Investigative [1]
Papillary renal cell carcinoma DC1NA56 ACHN Investigative [1]
Colon adenocarcinoma DC1L7KJ COLO 205 Investigative [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.